Levomefolate calcium

For research use only. Not for therapeutic Use.

  • CAT Number: I001879
  • CAS Number: 151533-22-1
  • Molecular Formula: C20H23N7O6 • Ca
  • Molecular Weight: 497.50
  • Purity: ≥95%
Inquiry Now

Levomefolate calcium (Cat No.:I001879) is the calcium salt of levomefolate, the active form of folate (vitamin B9) in the body. Levomefolate calcium is used as a dietary supplement or medication to provide a bioavailable form of folate for individuals who have deficiencies or have an increased need for folate. It plays a crucial role in various biological processes, including DNA synthesis and repair, red blood cell formation, and neural tube development in fetal growth. Levomefolate calcium is commonly prescribed to pregnant women to prevent neural tube defects in their babies. It may also be used in the management of certain types of anemia and for individuals with malabsorption or metabolic disorders affecting folate metabolism.


Catalog Number I001879
CAS Number 151533-22-1
Synonyms

calcium (S)-4-(4-(((S)-2-amino-5-methyl-4-oxo-1,4,5,6,7,8-hexahydropteridin-6-yl)(methyl)amino)benzamido)-4-carboxybutanoate 4-(4-(((S)-2-amino-5-methyl-4-oxo-1,4,5,6,7,8-hexahydropteridin-6-yl)(methyl)amino)benzamido)-4-carboxybutanoate

Molecular Formula C20H23N7O6 • Ca
Purity ≥95%
Target Antifolate
Solubility H2O: ≤ 4.4 mg/mL
Storage Store at -20°C
Related CAS 134-35-0(acid)    
IUPAC Name calcium;(2S)-2-[[4-[[(6S)-2-amino-5-methyl-4-oxo-3,6,7,8-tetrahydropteridin-6-yl]methylamino]benzoyl]amino]pentanedioate
InChI InChI=1S/C20H25N7O6.Ca/c1-27-12(9-23-16-15(27)18(31)26-20(21)25-16)8-22-11-4-2-10(3-5-11)17(30)24-13(19(32)33)6-7-14(28)29;/h2-5,12-13,22H,6-9H2,1H3,(H,24,30)(H,28,29)(H,32,33)(H4,21,23,25,26,31);/q;+2/p-2/t12-,13-;/m0./s1
InChIKey VWBBRFHSPXRJQD-QNTKWALQSA-L
SMILES CN1[C@H](CNC2=C1C(=O)NC(=N2)N)CNC3=CC=C(C=C3)C(=O)N[C@@H](CCC(=O)[O-])C(=O)[O-].[Ca+2]
Reference

1: Wiesinger H, Eydeler U, Richard F, Trummer D, Blode H, Rohde B, Diefenbach K.
Bioequivalence evaluation of a folate-supplemented oral contraceptive containing
ethinylestradiol/drospirenone/levomefolate calcium versus
ethinylestradiol/drospirenone and levomefolate calcium alone. Clin Drug Investig.
2012 Oct 1;32(10):673-84. doi: 10.2165/11635280-000000000-00000. PubMed PMID:
22909145.

</br>
2: Blode H, Klipping C, Richard F, Trummer D, Rohde B, Diefenbach K.
Bioequivalence study of an oral contraceptive containing
ethinylestradiol/drospirenone/levomefolate calcium relative to
ethinylestradiol/drospirenone and to levomefolate calcium alone. Contraception.
2012 Feb;85(2):177-84. doi: 10.1016/j.contraception.2011.05.015. Epub 2011 Jul
19. PubMed PMID: 22067789.

</br>
3: Diefenbach K, Trummer D, Ebert F, Lissy M, Koch M, Rohde B, Blode H.
EE-drospirenone-levomefolate calcium versus EE-drospirenone + folic acid: folate
status during 24 weeks of treatment and over 20 weeks following treatment
cessation. Int J Womens Health. 2013 Apr 11;5:149-63. doi: 10.2147/IJWH.S37254.
Print 2013. PubMed PMID: 23610531; PubMed Central PMCID: PMC3628530.

</br>
4: Rapkin RB, Creinin MD. The combined oral contraceptive pill containing
drospirenone and ethinyl estradiol plus levomefolate calcium. Expert Opin
Pharmacother. 2011 Oct;12(15):2403-10. doi: 10.1517/14656566.2011.610791. Epub
2011 Aug 31. Review. PubMed PMID: 21877996.

Request a Quote